Treatment of FGG related diseases and disorders
A siRNA-based composition targeting FGG effectively treats psychiatric and neurological disorders by reducing FGG expression, improving disease phenotypes and markers of neurodegeneration without significantly affecting coagulation.
WO2026122565A1 Publication Date: 2026-06-11EMPIRICO INC
2 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/057724
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-04
- Filing Date
- 2025-12-02
- Publication Date
- 2026-06-11
AI Technical Summary
Technical Problem
There is a need for improved therapeutics to treat psychiatric and neurological diseases, as existing treatments are inadequate.
Method used
A composition comprising an oligonucleotide, such as siRNA, is used to modulate the expression of fibrinogen gamma chain (FGG) by targeting it with a sense and antisense strand, potentially reducing FGG mRNA and protein levels in cells, tissues, and fluids to treat psychiatric and neurological disorders.
Benefits of technology
The oligonucleotide effectively decreases FGG levels, leading to significant improvements in psychiatric and neurological disease phenotypes, including reduced markers of neurodegeneration and fibrinogen levels, while minimizing effects on coagulation parameters.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
Need to check novelty before this filing date? Find Prior Art